NCT00037830View on ClinicalTrials.gov

GM1 Ganglioside Effects on Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Parkinson Disease
Interventions
DRUG

GM1 ganglioside

100 mg twice per day by subcutaneous injection

DRUG

Placebo

Twice per day subcutaneous injection, equal volume as active drug

Trial Locations (1)

19107

Parkinson's Disease Research Unit, Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Thomas Jefferson University

OTHER

NCT00037830 - GM1 Ganglioside Effects on Parkinson's Disease | Biotech Hunter | Biotech Hunter